Drugs / A/H7N9
A/H7N9
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03738241 | Dec 2018 → Jun 2020 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/H7N9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03738241 ↗ |
| Known as | 2017 A/H7N9 IIV | “one dose of a monovalent inactivated split influenza 2017 A/H7N9 virus vaccine (2017 A/H7N9 IIV), administered intramuscularly (IM) at 3.75 mcg hemagglutinin (HA) per dose” NCT03738241 ↗ |
| Known as | A/Hong Kong/125/2017 (H7N9) MIV | “Participants were randomized to receive 1 dose of AS03-adjuvanted or unadjuvanted A/Hong Kong/125/2017 (H7N9) MIV and were followed for safety and immunogenicity using...” PMID 37466221 ↗ Feb 2024 |
| Modality | Vaccine | “monovalent inactivated split influenza 2017 A/H7N9 virus vaccine” NCT03738241 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM) at 3.75 mcg hemagglutinin (HA) per dose” NCT03738241 ↗ |